Tamoxifen
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-TAMOXIFEN |
|---|---|
| Type | Drug |
| Aliases | NolvadexТамоксифен |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Drug Facts
| Class | SERM (selective estrogen receptor modulator) |
|---|---|
| Mechanism | Mixed agonist/antagonist at estrogen receptor — antagonist in breast tissue, agonist in bone, endometrium, and CV system. Classic adjuvant therapy for premenopausal HR+ breast cancer; also used in metastatic. |
| Typical dosing | 20 mg PO once daily for 5-10 years adjuvant (premenopausal); continued in metastatic until progression. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Standard of care for premenopausal HR+ adjuvant. Switch to AI ± ovarian suppression after 2-5 years often considered. Postmenopausal: AI generally preferred but tamoxifen acceptable when AI contraindicated.
Used By
No reverse references found in the YAML corpus.